EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine

Chun-Fu Lin iD, Chen-Chih Chung iD, Jia-Hung Chen, Nai-Fang Chi, Chaur-Jong Hu iD, Hung-En Huang, Chih-Chung Chen, Tu-Hsueh Yeh iD, James Cheng-Chung Wei, Hsun-Hua Lee

Journal of Clinical Medicine · 25.06.2026 · 15 (13) · 4963

DOI: 10.3390/jcm15134963 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.06.2026. Verfasst von Chun-Fu Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Taipei Medical University Hospital, Taipei Medical University, Taipei 110301, Taiwan. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

OnabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal antibodies are widely used for chronic migraine prevention, but comparative real-world evidence on healthcare utilization remains limited. This study aimed to compare the association of onabotulinumtoxinA versus CGRP monoclonal antibodies with acute triptan prescription and migraine-related return visits in patients with chronic migraine.

Methods

We conducted a retrospective cohort study using the TriNetX global federated electronic health record database from 2018 to 2024. Adults with chronic migraine who initiated onabotulinumtoxinA or a CGRP monoclonal antibody were matched 1:1 by propensity score. The primary outcomes were time to acute triptan prescription and time to first migraine-related return visit during follow-up.

Results

After propensity score matching, 10,140 patients were included in each treatment group. OnabotulinumtoxinA was associated with a lower hazard of acute triptan prescription than CGRP monoclonal antibodies (hazard ratio 0.513, 95% confidence interval 0.481–0.546; p < 0.001), whereas migraine-related return visits were similar between groups (hazard ratio 1.008, 95% confidence interval 0.977–1.039; p = 0.69).

Conclusions

In this multicenter real-world analysis, onabotulinumtoxinA was associated with a lower hazard of acute triptan prescription than CGRP monoclonal antibodies, while migraine-related return visits were comparable. These findings reflect treatment-related healthcare utilization patterns in routine practice and should be interpreted considering the limitations of retrospective electronic health record data.

Schlagwörter

Stichwörter der Autor:innen

CGRP monoclonal antibodieschronic migraineonabotulinumtoxinApropensity score matchingreal-world evidence

Autor:innen und Institutionen

  • Department of Neurology, Taipei Medical University Hospital, Taipei Medical University, Taipei 110301, Taiwan.
  • Dizziness and Balance Disorder Center, Taipei Medical University Hospital, Taipei Medical University, New Taipei City 235061, Taiwan.
  • Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan.
  • Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, Taiwan.
  • Department of Neurology, Neurological Institute and Stroke Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.

ORCID-Profile: Chun-Fu Lin, Chen-Chih Chung, Chaur-Jong Hu, Tu-Hsueh Yeh

Zitieren

APA

Lin, C. F., Chung, C. C., Chen, J. H., Chi, N. F., Hu, C. J., Huang, H. E., Chen, C. C., Yeh, T. H., Wei, J. C., & Lee, H. H. (2026). Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine. Journal of Clinical Medicine, 15(13), 4963. https://doi.org/10.3390/jcm15134963

Vancouver

Lin CF, Chung CC, Chen JH, Chi NF, Hu CJ, Huang HE, et al. Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine. Journal of Clinical Medicine. 2026;15(13):4963. doi:10.3390/jcm15134963

BibTeX
@article{Lin2026,
  author = {Lin, Chun-Fu and Chung, Chen-Chih and Chen, Jia-Hung and Chi, Nai-Fang and Hu, Chaur-Jong and Huang, Hung-En and Chen, Chih-Chung and Yeh, Tu-Hsueh and Wei, James Cheng-Chung and Lee, Hsun-Hua},
  title = {Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {4963},
  doi = {10.3390/jcm15134963}
}
Kostenlos starten →